Log in

NASDAQ:MRTXMirati Therapeutics Stock Price, Forecast & News

$116.99
-0.58 (-0.49 %)
(As of 07/3/2020 09:42 AM ET)
Add
Compare
Today's Range
$115.73
Now: $116.99
$119.44
50-Day Range
$93.41
MA: $105.36
$120.39
52-Week Range
$66.01
Now: $116.99
$132.59
Volume220,046 shs
Average Volume483,869 shs
Market Capitalization$5.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More
Mirati Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.34 million
Book Value$9.67 per share

Profitability

Net Income$-213,260,000.00
Net Margins-10,983.84%

Miscellaneous

Employees63
Market Cap$5.11 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

How has Mirati Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRTX shares have increased by 51.2% and is now trading at $116.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mirati Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mirati Therapeutics.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mirati Therapeutics.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($2.02) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.66) by $0.36. The biotechnology company earned $0.27 million during the quarter, compared to analyst estimates of $0.29 million. Mirati Therapeutics had a negative return on equity of 53.25% and a negative net margin of 10,983.84%. Mirati Therapeutics's revenue was down 78.5% on a year-over-year basis. View Mirati Therapeutics' earnings history.

What price target have analysts set for MRTX?

14 brokerages have issued 1-year price targets for Mirati Therapeutics' stock. Their forecasts range from $83.00 to $151.00. On average, they expect Mirati Therapeutics' share price to reach $111.46 in the next year. This suggests that the stock has a possible downside of 4.7%. View analysts' price targets for Mirati Therapeutics.

Has Mirati Therapeutics been receiving favorable news coverage?

Media coverage about MRTX stock has trended negative on Friday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Mirati Therapeutics.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), DexCom (DXCM), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Paypal (PYPL), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $116.99.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $5.11 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.